RoosterVial™-hUC-XF is the Regenerative Medicine industry’s first xeno-free human umbilical cord mesenchymal stem/stromal cell (hMSC) bioprocess system designed to meet the quality and volume needs of today’s translationally focused product developers.
FREDERICK, MD. (PRWEB) SEPTEMBER 06, 2019
RoosterBio, Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announces its release of the Regenerative Medicine industry’s first human umbilical cord (hUC) MSC paired cell and media system designed for product development. RoosterBio continues to simplify MSC production by introducing an unprecedented step-change in quantifiable productivity metrics. RoosterVial™-hUC-MSC-XF, allows scientists to generate billions of perinatal cells in a fraction of the time when paired with RoosterBio’s existing xeno-free hMSC plug and play systems. This product line is the only commercially available, high-volume perinatal MSC bioprocess system with a line of sight to towards clinical translation.
“Until now, there was not a hUC-MSC on the market that would support the quality and scale needs of cell therapy product developers,” said RoosterBio Founder & Chief Product Officer Jon A. Rowley, PhD. RoosterBio’s launch of RoosterVial-hUC-MSC-XF introduces another first-in-class hMSC product on the market that simplifies all aspects of product development. “This very powerful set of biological tools has now been released into the Regenerative Medicine marketplace, introducing a major step-change in MSC productivity,” added Dr. Rowley.
The adoption of umbilical cord hMSC product development in Asia and Europe has demonstrated hUC-MSCs are the fastest growing tissue type and second in overall usage within hMSC Regenerative Medicine applications, according to recent global research publications. hUC-MSC product development in North America has been slower to develop due to the lack of availability of this critical raw material.
RoosterBio’s xeno-free hUC-MSCs are isolated from the perivascular Wharton’s Jelly region of the human umbilical cord and is collected after birth. “RoosterBio’s first-in-class characterization of hUC-MSC key quality attributes along with our readily implementable process recommendations gives added confidence in quality, reproducibility, and ease of integration,” said Dr. Rowley. “By introducing new tissue types, we are opening the door to support the incorporation of these new living cellular technologies into product development across the globe.”
Along with RoosterBio’s paired bioprocess media system, RoosterVial-hUC reaches new levels in hMSC expansion in terms of M cells/L media consumed as well as extracellular vesicle (EV) productivity. The product is backed by licensed intellectual property (IP) from Tissue Regeneration Therapeutics (TRT), a Canadian Controlled Private Corporation with a focus on Human Umbilical Cord PeriVascular Cell (HUCPVC) technology.
RoosterBio announced the collaboration with Tissue Regeneration Therapeutics in May 2019 which gave RoosterBio an exclusive worldwide license to TRT’s patent estate related to the manufacture and global sale of human umbilical cord-derived MSCs. The announcement advances both companies shared goal of accelerating the development of the Regenerative Medicine industry.
Visit https://www.roosterbio.com/collections/high-volume-hmscs for more information about RoosterBio’s radically simplified xeno-free hUC-MSCs.
About RoosterBio, Inc
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.
This very powerful set of biological tools has now been released into the Regenerative Medicine marketplace, introducing a major step-change in MSC productivity – Jon A. Rowley, PhD, Founder & CPO, RoosterBio
